A Placebo-Controlled Study of INS117548 Ophthalmic Solution in Subjects With Glaucoma (P08650)
NCT ID: NCT00767793
Last Updated: 2015-10-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
84 participants
INTERVENTIONAL
2008-09-30
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or Glaucoma
NCT00443924
H-1337 Ophthalmic Solution Phase 1/2
NCT03452033
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
NCT01123785
A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma
NCT02743780
Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
NCT03233308
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
One drop in each eye every 12 hours for seven days
Placebo
One drop in each eye every 12 hours for seven days
Arm 2
One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
INS117548
One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
Arm 3
One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
INS117548
One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
Arm 4
One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
INS117548
One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
One drop in each eye every 12 hours for seven days
INS117548
One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
INS117548
One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
INS117548
One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have best corrected visual acuity in both eyes of at least +0.5 or better
Exclusion Criteria
* Have a history of any type of intraocular surgery, except for cataract surgery
* Have had cataract surgery within three months
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Reza Haque, MD, PhD
Role: STUDY_DIRECTOR
Medical Monitor, Inspire
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
037-101
Identifier Type: -
Identifier Source: secondary_id
P08650
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.